BOTHELL, Wash., April 15, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced that Cord Blood Registry (CBR^®), the world's largest newborn stem cell company, uses BioLife's CryoStor clinical grade cryopreservation freeze media in its process for cryogenic storage of umbilical cord tissue stem cells.

Storage of umbilical cord tissue is a product currently offered by a limited number of cord blood banks throughout the world. While umbilical cord blood is a source of hematopoietic (blood) stem cells, umbilical cord tissue is a rich source of mesenchymal stem cells, which have the ability to differentiate into cells of the connective tissue including osteoblasts (bone-forming cells), chondrocytes (cartilage cells), and adipocytes (fat cells).

Geoffrey Crouse, President and Chief Executive Officer of CBR and a founding board member of the recently formed Cord Blood Association, remarked on the use of CryoStor by stating, "Families entrust CBR with their newborn cord tissue samples because of our dedication to and reputation for high quality. We insist on that same level of quality from our partners, which is why we utilize BioLife Solutions for the preservation of cord tissue."

Mike Rice, BioLife Solutions CEO, remarked, "CBR pioneered the storage of umbilical cord blood and tissue and is the established leader in personalized storage of newborn stem cells. We are very pleased to count CBR among our most highly valued customers and look forward to identifying opportunities to expand our relationship."

About Cord Blood Registry

Cord Blood Registry® (CBR®) is the world's largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing more than 500,000 cord blood and cord tissue units. CBR is dedicated to advancing the clinical application of newborn stem cells by partnering with leading research institutions to establish FDA-regulated clinical trials, requiring CBR processed cord blood, for conditions that have no cure today. For more information, visit cordblood.com

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol^® and CryoStor^® biopreservation media products are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's proprietary products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. This enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, projected financial results, new products, and third party projections regarding the future market for regenerative medicine and cold chain packaging and instrumentation services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; reliance upon SAVSU for completing the development and manufacturing of biologistex CCM's products; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

SOURCE BioLife Solutions, Inc.